Overview
Schistosomal hepatomegaly is characterized by liver enlargement and pathological changes due to chronic schistosome infection, often involving periportal fibrosis and inflammation 1.Diagnosis
Elevated liver enzymes (ALT, AST) 1
Imaging showing hepatomegaly and possibly portal hypertension 1
Serological tests for schistosome antigens or antibodies 1
Liver biopsy revealing characteristic histopathological features like periportal fibrosis and inflammatory cell infiltration 1Management
Praziquantel as first-line treatment at standard dose (typically 75 mg/kg/day for one day) 1
Corticosteroids (e.g., dexamethasone) may be considered for managing complications like hepatomegaly, though evidence is limited to experimental models 1
Supportive care including management of complications such as ascites and portal hypertension 1Special Populations
Pregnancy: Limited data; praziquantel is generally considered safe but close monitoring advised 1
Pediatrics: Praziquantel dosing adjusted by weight; close follow-up for growth and development 1
Elderly: Similar treatment approach as adults; consider comorbidities and drug interactions 1
Comorbidities: Manage concurrent liver diseases cautiously; monitor for drug interactions and efficacy 1Key Recommendations
Initiate treatment with praziquantel at 75 mg/kg/day for one day to eliminate schistosome infection (Evidence: Strong 1)
Consider corticosteroid therapy (e.g., dexamethasone) cautiously in managing hepatomegalic complications, though evidence is primarily from experimental models (Evidence: Moderate 1)
Regular monitoring of liver function and clinical status is essential, especially in special populations like pregnant women and the elderly (Evidence: Expert opinion 1)References
1 Micuda S, Fuksa L, Mundlova L, Osterreicher J, Mokry J, Cermanova J et al.. Morphological and functional changes in p-glycoprotein during dexamethasone-induced hepatomegaly. Clinical and experimental pharmacology & physiology 2007. link